PANCREATIC NEUROENDOCRINE CARCINOMA
Clinical trials for PANCREATIC NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: PANCREATIC NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill shows promise against tough cancers in early trial
Disease control OngoingThis Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…
Matched conditions: PANCREATIC NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New chemo combo tested for rare gut cancers – results disappoint
Disease control OngoingThis phase 2 trial tested whether a combination of temozolomide and capecitabine works better than the standard cisplatin and etoposide for people with advanced, hard-to-treat gastrointestinal neuroendocrine carcinomas. The study enrolled 67 participants whose cancer had spread o…
Matched conditions: PANCREATIC NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for rare pancreatic cancer: experimental drug enters trial
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called lurbinectedin in people with high-grade pancreatic neuroendocrine tumors (a rare, fast-growing cancer) who have already tried standard treatments. The goal is to see if the drug can shrink tumors or stop them from growing. About 46 adults will take …
Matched conditions: PANCREATIC NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC